-
Start Preamble
ACTION:
Notice of registration.
SUMMARY:
Registrant listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as importers of various classes of schedule I or II controlled substances.
End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
The company listed below applied to be registered as an importer of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for these notices.
Company FR Docket Published Galephar Pharmaceutical Research Inc 83 FR 37525 August 1, 2018. The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrant to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing each company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.
Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or II controlled substance to the above listed company.
Start SignatureDated: September 24, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-22420 Filed 10-12-18; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 10/15/2018
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Action:
- Notice of registration.
- Document Number:
- 2018-22420
- Pages:
- 51983-51983 (1 pages)
- Docket Numbers:
- Docket No. DEA-392
- PDF File:
- 2018-22420.pdf